Oncolytic Immunotherapy Cuts Bladder Cancer Recurrence to 25%

Phase 3 clinical trial data demonstrates sharp reductions in tumor recurrence, highlighting how targeted biological platforms alter longevity outcomes for non-muscle invasive disease.

By Sabin · Wellness & AI3 min read
AI News
Oncolytic Immunotherapy Cuts Bladder Cancer Recurrence to 25%

Final cohort data from a phase 3 study of cretostimogene grenadorepvec, an oncolytic virus immunotherapy, demonstrated a 75% complete response rate at 12 months in 116 patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer. Progression to radical cystectomy was averted in over 90% of responders.

The viral therapy selectively replicates within retinoblastoma-deficient malignant cells, lysing them while releasing granulocyte-macrophage colony-stimulating factor to stimulate localized immune surveillance. For patients facing bladder removal, preserving the organ directly safeguards long-term functional independence, urinary continence, and systemic vitality.

Bladder cancer recurrence typically demands rigorous cystoscopic surveillance every three months. The physical burden and diagnostic anxiety of continuous invasive monitoring often leads to procedural fatigue, causing missed appointments and delayed detection of high-grade recurrences.

Long-term health span requires actively defending your native physiology. If you manage a chronic or recurring urothelial condition, discuss urinary liquid-biopsy marker tracking with your specialist to monitor treatment response prior to visible anatomical changes.

One headline rarely tells the story. See how today’s news fits the bigger shifts on AI Trends, or learn to read your own data on How it works.

Keep reading

Based on what you've been reading — always learning.

See all →